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ABSTRACT 
 
 This thesis describes development of a catalyst system that allows formation of 
compounds containing bis-benzylic quaternary stereocenters. The work presented herein 
describes studies towards development of enantioselective, palladium-catalyzed conjugate 
additions of arylboronic acids to β-aryl, β,β-disubstituted enones to generate ketones 
containing bis-benzylic quaternary stereocenters. A catalyst generated in situ from palladium 
trifluoroacetate and a chiral, non-racemic (S)-4-tert-butyl-2-(2-pyridyl)oxazoline ligand ((S)-
t-BuPyOx) promotes conjugate additions of a wide range of electronically and structurally 
diverse arylboronic acids to a variety of β-aryl, β,β-disubstituted enones. In this work, we 
have used iterative addition of the arylboronic acids as a strategy to minimize undesired 
protodeboronation pathways that leads to efficient formation of the corresponding ketones 
containing bis-benzylic quaternary stereocenters in up to 92% yield with up to 93% 
enantioselectivity.  
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CHAPTER I 
INTRODUCTION 
 
A Brief Overview of Development of Transition Metal-Catalyzed Conjugate Additions 
of Organometallic Nucleophiles to Access Benzylic and Bis-Benzylic Quaternary 
Stereocenters 
 
Transition metal-catalyzed conjugate addition of organometallic nucleophiles is a 
reliable and practical approach to form benzylic quaternary centers.1 Over the past decades, 
many research groups have developed enantioselective, transition metal-catalyzed conjugate 
addition reactions of various organometallic aryl nucleophiles using nickel, copper, rhodium 
and palladium catalysts.2  
Nickel-catalyzed conjugate additions of arylaluminum compounds represent an early 
example of transition metal-catalyzed conjugate additions of organometallic nucleophiles to 
generate compounds containing benzylic quaternary centers (Scheme 1).3  
 
Scheme 1. Nickel-catalyzed conjugate additions of arylaluminum compounds to generate 
compounds containing benzylic quaternary centers 
 
Pioneering work by Hoveyda and Alexakis led to the development of 
enantioselective, copper-catalyzed conjugate additions of arylzinc,4 arylmagnesium,5 and 
arylaluminum6 nucleophiles to β,β-disubstituted enones to access benzylic quaternary 
stereocenters (Scheme 2). However, these nickel- and copper-catalyzed conjugate addition 
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reactions involve use of highly reactive, air and/or moisture sensitive organometallic 
nucleophiles. Thus, they have limited functional group tolerance.  
 
Scheme 2. Enantioselective, copper-catalyzed conjugate additions of aryl nucleophiles to 
generate compounds containing benzylic quaternary stereocenters 
 
 Hayashi and Glorius have independently developed enantioselective conjugate 
addition reactions catalyzed by rhodium catalysts that use air stable and easily handled 
arylboron nucleophiles to generate compounds containing benzylic quaternary sterocenters in 
high yields and enantioselectivities (Scheme 3).7 However, rhodium-catalyzed additions of 
commercially available arylboronic acids are not efficient in these systems.  
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Scheme 3. Enantioselective, rhodium-catalyzed conjugate additions of arylboron compounds 
to generate compounds containing benzylic quaternary stereocenters 
 
 Lu and coworkers reported first examples of palladium-catalyzed conjugate additions 
of arylboronic acids to generate compounds containing benzylic quaternary centers (Scheme 
4). In this work, Lu and coworkers use a cationic bipyridine ligated palladium complex to 
catalyze additions of arylboronic acids to β,β-disubstituted enones to form compounds 
containing benzylic quaternary centers in high yields.8  
 
Scheme 4. Palladium-catalyzed conjugate additions of arylboronic acids to generate 
compounds containing benzylic quaternary centers  
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Stoltz and Minnaard have independently developed chiral palladium catalysts that 
catalyze additions of arylboronic acids to generate compounds containing benzylic 
stereocenters (Scheme 5).9 These reactions use complexes generated in situ from palladium 
trifluoroacetate and chiral, non-racemic bidentate nitrogen-containing ligands, such as chiral 
pyridine-oxazolines and bisoxazolines, that catalyze additions of a wide array of arylboronic 
acids to generate ketones containing benzylic quaternary stereocenters in high yields and 
enantioselectivities.  
 
Scheme 5. Enantioselective, palladium-catalyzed conjugate additions of arylboronic acids to 
generate compounds containing benzylic quaternary stereocenters 
 
However, there are no examples of enantioselective, palladium-catalyzed conjugate 
additions of arylboronic acids to generate compounds containing bis-benzylic quaternary 
stereocenters. In fact, previous attempts to generate compounds containing bis-benzylic 
quaternary stereocenters using chiral palladium catalyst have been unsuccessful.9d  
 In 2013, Hoveyda reported copper-catalyzed conjugate additions of arylaluminum 
compounds to β-aryl, β,β-disubstituted acyclic enones to generate acyclic ketones containing 
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bis-benzylic quaternary stereocenters (Scheme 6).10 However, these reactions use air and/or 
moisture sensitive arylaluminum nucleophiles and thus, have low functional group tolerance. 
In addition, no examples of additions to β-aryl, β,β-disubstituted cyclic enones have been 
reported in this work. 
 
Scheme 6. Enantioselective, copper-catalyzed conjugate additions of arylaluminum 
compounds to generate compounds containing bis-benzylic quaternary stereocenters 
 
 Our recent development of palladium-catalyzed conjugate additions of arylboronic 
acids to β-aryl, β,β-disubstituted enones in an aqueous media to access bis-benzylic 
quaternary centers prompted us to develop an enantioselective variant of this method 
(Scheme 7).11  
  
Scheme 7. Palladium-catalyzed conjugate additions of arylboronic acids in aqueous media to 
generate compounds containing bis-benzylic quaternary centers 
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This thesis details the work towards development of enantioselective, palladium-
catalyzed conjugate additions of arylboronic acids to β-aryl, β,β-disubstituted enones. In this 
work, we have used iterative addition of arylboronic acids as a strategy to minimize 
protodeboronation of arylboronic acids (Scheme 8, A), which is a major unproductive 
pathway in pd-catalyzed conjugate additions of arylboronic acids, that led to efficient 
formation of compounds containing bis-benzylic quaternary stereocenters in up to 92% yield 
and 93% enantioselectivities (Scheme 8, B). 
 
 
 
 
Scheme 8. Enantioselective, palladium-catalyzed conjugate additions of arylboronic acids to 
β-aryl β,β-disubstituted enones 
 
Thesis organization 
 This thesis contains three chapters. Chapter 1 is a general introduction to the 
chemistry described in the thesis. Chapter 2 describes research work that has not been 
submitted for publication at this time. Chapter 3 is a conclusion chapter for the thesis. 
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CHAPTER 2 
 
ENANTIOSELECTIVE, PALLADIUM-CATALYZED CONJUGATE ADDITIONS OF 
ARYLBORONIC ACIDS TO FORM BIS-BENZYLIC QUATERNARY 
STEREOCENTERS 
 
Abhishek A. Kadam, Arkady Ellern and Levi M. Stanley*  
Department of Chemistry, Iowa State University, Ames, Iowa 50011, United States. 
 
Abstract  
 
We report enantioselective, palladium-catalyzed conjugate additions of arylboronic 
acids to β-aryl, β,β-disubstituted enones to generate ketones containing bis-benzylic 
quaternary stereocenters. A catalyst generated from palladium trifluoroacetate and a chiral, 
non-racemic (S)-4-tert-butyl-2-(2-pyridyl)oxazoline ligand ((S)-t-BuPyOx) promotes 
conjugate additions of a wide range of arylboronic acids to a variety of β-aryl, β,β-
disubstituted enones.  Iterative addition of the arylboronic acid nucleophile to minimize 
undesired protodeboronation pathways leads to efficient formation of the corresponding 
ketones containing bis-benzylic quaternary stereocenters in up to 92% yield with up to 92% 
enantioselectivity. 
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General Introduction 
Compounds containing bis-benzylic quaternary centers are present in an array of 
biologically active compounds1 (Figure 1) and are a structural motif found in the cardo class 
of polymers.2 Enantioselective, transition metal-catalyzed conjugate addition reactions of 
organometallic nucleophiles to β,β-disubstituted enones are a powerful approach to form 
compounds containing quaternary stereocenters.3 Despite recent advances in 
enantioselective, transition metal-catalyzed conjugate additions of organometallic 
nucleophiles, analogous asymmetric additions to β-aryl β,β-disubstituted enones to form bis-
benzylic quaternary stereocenters remain challenging.  
 
 
Figure 1. Biologically active compounds containing bis-benzylic quaternary stereocenters 
 
 
Over the past decades, enantioselective conjugate additions of arylzinc,4 
arylaluminum,5 arylmagnesium,6 and arylboron7 nucleophiles to β,β-disubstituted enones in 
the presence of chiral copper, rhodium, and palladium catalysts have been developed as 
practical methods to synthesize compounds containing benzylic quaternary stereocenters. 
However, examples of enantioselective, transition metal-catalyzed conjugate additions of 
aryl organometallic nucleophiles to β-aryl β,β-disubstituted enones to generate compounds 
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containing bis-benzylic quaternary stereocenters are currently limited to copper-catalyzed 
additions to acyclic electrophiles. In 2013, Hoveyda and coworkers reported copper-
catalyzed conjugate additions of arylaluminum compounds to β-aryl β,β-disubstituted acyclic 
enones to form acyclic ketones containing bis-benzylic quaternary stereocenters with good-
to-excellent enantioselectivity (Scheme 1A).5a In this report, however, there are no examples 
of additions of arylaluminum nucleophiles to β-aryl β,β-disubstituted cyclic enones. In 
addition, these copper-catalyzed conjugate addition reactions use highly air and/or moisture 
sensitive arylaluminum nucleophiles and thus, have low functional group tolerance. 
 
 
Scheme 1. Enantioselective, transition-metal catalyzed conjugate additions of aryl 
nucleophiles to β-aryl, β,β-disubstituted enones 
 
We recently reported palladium-catalyzed conjugate additions of bench stable and 
commercially available arylboronic acids to β,β-disubstituted enones in aqueous media.8 This 
approach enables additions of arylboronic acids to β-aryl β,β-disubstituted cyclic enones to 
form an array of ketones with bis-benzylic quaternary centers in moderate-to-high yields (54-
74%).  However, efforts from our group and others7d to develop enantioselective variants of 
these reactions have been limited by modest enantioselectivity in aqueous media, poor 
reactivity in organic solvents, and competing decomposition of the arylboronic acid 
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nucleophile. We now report catalytic, enantioselective additions of arylboronic acids to β-
aryl β,β-disubstituted cyclic enones that occur in up to 92% yield with high enantioselectivity 
and minimize undesired pathways for nucleophile decomposition (Scheme 1B). 
 
Results and discussion: 
At the outset of our studies, we chose 3-(4-methoxyphenyl)-cyclohexen-2-one 1a and 
phenylboronic acid as our model substrates to optimize palladium-catalyzed conjugate 
addition reactions. Evaluation of chiral, non-racemic pyridine-oxazoline and bisoxazoline 
ligands showed that reactions conducted in the presence of palladium trifluoroacetate and 
(S)-t-BuPyOx formed the ketone product with highest ee (Table 1, entries 1-6) at 80 °C in aq. 
NaTFA solution. However, when these reactions were conducted in organic solvents, yield 
and enantioselectivity of the reaction increased (Table 1, entries 7-9). Addition of 4 equiv of 
phenylboronic acid to 1a at 90 °C formed 3-(4-methoxyphenyl)-3-(4-phenyl)cyclohexanone 
2a in 39% yield with 91% ee (Table 1, entry 10). However, when the same reaction was 
conducted in the presence of 1 equiv of phenylboronic acid, the reaction generated the ketone 
product 2a in nearly identical 38% yield and 91% ee in 3 h (Table 1, entry 11).  This result 
suggests that there are potential unproductive pathways involved in this reaction. Palladium-
catalyzed conjugate additions of arylboronic acids are often plagued by protodeboronation of 
arylboronic acid that can occur through multiple pathways.9  To investigate formation of 
byproducts in this reaction, we conducted control experiments using 4-tolylboronic acid. 
Indeed, when 4-tolylboronic acid was exposed to the reaction conditions in the absence of 
enone 1a, toluene was formed in nearly 75% yield in the presence of the catalyst. However, 
in the absence of the catalyst, <5% toluene formation of observed (Figure 2).  
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Table 1. Initial optimization studies 
 
 
 
 
 
 
Entry Temp (°C) Ligand Solvent Yield 2ab % eec 
1 80 (R)-PhBox aq. NaTFA (pH = 8.2) 0 - 
2 80 (S)-t-BuBox aq. NaTFA (pH = 8.2) 0 - 
3 80 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 17 77 
4 80 (S)-i-PrPyOx aq. NaTFA (pH = 8.2) 21 49 
5 100 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 8d - 
6 60 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 4 71 
7 80 (S)-t-BuPyOx 1,2-Dichloroethane 34 88 
8e 80 (S)-t-BuPyOx 1,2-Dichloroethane 34 91 
9e 80 (S)-t-BuPyOx Methanol 36 84 
10e 90 (S)-t-BuPyOx 1,2-Dichloroethane 39 91 
11f 90 (S)-t-BuPyOx 1,2-Dichloroethane 38 91 
aReaction conditions: 3-(4-Methoxyphenyl)-cyclohex-2-enone (0.30 mmol), 
phenylboronic acid (1.2 mmol), Pd(TFA)2 (0.015 mmol), ligand (0.018 mmol) run in 0.1 
mL of solvent for 24 h. bIsolated yields. cDetermined by chiral HPLC analysis. dYield 
determined by 1H NMR using dibromomethane as an internal standard. eReaction run in 
0.6 mL of solvent. fReaction conducted with 1 equiv of phenylboronic acid, time = 3 h. 
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Figure 2. Control experiments: Protodeboronation studies 
 
We then selected the addition of 4-tolylboronic acid to 3-(4-methoxyphenyl)-
cyclohex-2-enone 1a in the presence of 5 mol % of the catalyst generated from Pd(TFA)2 and 
(S)-t-BuPyOx as a model reaction that would facilitate straightforward analysis of reaction 
products and byproducts. To this point, the addition of 4 equiv of 4-tolyboronic acid to 1a led 
to protodeboronation of 43% of the total tolylboronic acid, formation of 2% of the 
homocoupling byproduct 4,4ʹ-dimethyl-1,1ʹ-biphenyl, and oxidation of 1a to form 4% 3-(4-
methoxyphenyl)phenol. When the model reaction was conducted with 1 equiv of 4-
tolylboronic acid, the reaction generated 2b in nearly identical 45% yield and 89% ee. The 
formation of 25% toluene through protodeboronation and small amounts (<5%) of 4,4ʹ-
dimethyl-1,1ʹ-biphenyl and 3-(4-methoxyphenyl)-phenol were also observed. We further 
optimized the reaction using 1 equiv of 4-tolylboronic acid. 
15 
 
Evaluation of palladium precursors: 
We next evaluated the effect of different palladium precursors on our model reaction. 
Reactions conducted with PdCl2 and Pd(CH3CN)2Cl2 did not form the ketone product 2b. 
However, when 12 mol % of AgTFA was added to these reactions, the reactions formed 
product 2b in identical yields and ee along with 16-19% toluene. However, reactions 
conducted with Pd(TFA)2 generated the ketone product in 45% yield and 89% ee along with 
26% toluene. Reactions conducted with Pd(OAc)2 generated 7% yield of 2b and 48% yield 
of toluene. Thus, we decided to carry out further optimization studies with Pd(TFA)2 as a 
palladium(II) precursor of choice. Less than 5% of 4,4ʹ-dimethyl-1,1ʹ-biphenyl and 3-(4-
methoxyphenyl)-phenol were observed in these reactions. 
Table 2. Evaluation of palladium precursors 
 
 
Entry pd precursor yield 2bb yield 3ac 2b/3a % eed 
1 PdCl2 0 2 0 - 
2 Pd(CH3CN)2Cl2 0 4 0 - 
3
e
 PdCl2, AgTFA 34 16 2.1:1.0 89 
4
e
 Pd(CH3CN)2Cl2, AgTFA 35 19 1.8:1.0 90 
5 Pd(TFA)
2
 45 26 1.7:1.0 89 
6 Pd(OAc)
2
 7b 48 0.1:1.0 - 
aReaction conditions: 1a (1.0 equiv), Pd precursor (5 mol %), (S)-t-BuPyOx (6 mol %), 
1,2-dichloroethane (0.5 M), 3 h. bIsolated yields. cYield determined by gas 
chromatography. dDetermined by chiral HPLC analysis. e12 mol% AgTFA was used.  
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Impact of water: 
 
We then studied the impact of water on protodeboronation of arylboronic acids. In the 
absence of enone 1a and any external water (neglecting the water present in the moisture in 
air and from glassware), protodeboronation of 4-tolylboronic acid occurred to form 75% 
yield of toluene when exposed to the catalyst. We observed a decrease in protodeboronation 
of 4-tolylboronic acid when additional water was added to the control reaction. When 4-
tolylboronic acid was exposed to the catalyst and 5 equiv of water, protodeboronation 
decreased by nearly 35%. The reaction formed only 14% toluene when 15 equiv of water was 
used.  
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Figure 3. Control experiments: Impact of water on protodeboronation 
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We then set out to the study palladium-catalyzed conjugate additions of 4-
tolylboronic acid to enone 1a in the presence of water. The results of these experiments are 
summarized in Table 3. The reaction generated ketone product 2b in nearly identical yields 
and ee when the reaction was conducted in the absence of any additional water and in the 
presence of 5 equiv of water (Entries 1 & 2). We presume the water present in the air and 
from glassware is sufficient to turn over the active catalyst. This is in accordance with 
previously reported palladium-catalyzed conjugate addition studies.7e A decrease in yield of 
2b and 3a was observed when the reaction was conducted in the presence of 10 and 15 equiv 
of water. Less than 5% of 4,4ʹ-dimethyl-1,1ʹ-biphenyl and 3-(4-methoxyphenyl)-phenol were 
observed in these reactions. 
Table 3. Impact of water  
 
 
Entry water (equiv.) yield 2bb yield 3ac 2b/3a % eed 
1
 
- 45 26 1.7:1.0 89 
2 5  47 27 1.7:1.0 87 
3 10 26 18 1.4:1.0 87 
4 15 28 17 1.6:1.0 87 
aReaction conditions: 1a (1.0 equiv), 4-tolylboronic acid (1.0 equiv), Pd(OTFA)2 (5.0 
mol %), (S)-t-BuPyOx (6.0 mol %), 1,2-dichloroethane (0.5 M), 3 h. bIsolated yields. 
cYield determined by gas chromatography. dDetermined by chiral HPLC analysis.   
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Impact of oxygen: 
 Pd(0) species are known to be inactive towards conjugate additions of arylboronic 
acids. Formation of Pd(0) species through homocoupling of 4-tolylboronic acid to 4,4ʹ-
dimethyl-1,1ʹ-biphenyl 4a and oxidation of 1a to 3-(4-methoxyphenyl)-phenol 5a can have 
deleterious effect on the efficiency of palladium-catalyzed conjugate addition reactions of 
arylboronic acids. Our data supports that the oxygen present in the air is sufficient to oxidize 
Pd(0) back to active Pd(II) catalyst. This is supported by the results presented in Table 4. 
Reactions conducted in the presence of 1 atm of oxygen and air formed the ketone product 
2b and toluene in nearly identical yields (Entries 1 and 2). However, when the reaction was 
conducted in an oxygen free environment, the yield of the reaction decreased. The reaction 
formed the ketone product 2b in 25% yield (Entry 3).  
Table 4. Impact of oxygen  
 
 
Entry reaction 
atmosphere 
yield 2bb yield 3ac 2b/3a yield 4ac yield 5ac % eed 
1 O2 (1 atm) 42 12 3.2:1.0 1 4 89 
2 Air 40 10 3.3:1.0 1 4 89 
3e O2 free 25 8 2.9:1.0 1 2 91 
aReaction conditions: 1a (1.0 equiv), 4-tolylboronic acid (1.0 equiv), Pd(OTFA)2 (5.0 mol 
%), (S)-t-BuPyOx (6.0 mol %), 1,2-dichloroethane (0.5 M), 3 h. bIsolated yields. cYield 
determined by gas chromatography. dDetermined by chiral HPLC analysis. eReaction set 
up in the glovebox, 1,2-dichloroethane was degassed using freeze-pump-thaw technique 
before use.   
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Identification of reaction conditions: 
We next studied the impact of reaction temperature on the relative rate of 
protodeboronation to conjugate addition (Table 5, entries 1-5). The amount of toluene 
generated decreases with lower reaction temperature. The best ratios of ketone 2b: toluene 3a 
(4.2-4.7:1) are observed at 60-80 °C, and the reactions generate 2b in 42% yield and 89-91% 
ee (entries 2-3). Increasing the reaction time (entry 5) and the reaction concentration (entry 6) 
led to modest improvement in the yield of 2b without increasing the rate of 
protodeboronation. 
To increase the yield of 2b to synthetically useful levels, we adopted an iterative 
addition strategy to maintain low concentrations of tolylboronic acid and hence a low rate of 
protodeboronation (entries 7-10). These reactions were conducted by starting the reaction 
with 1 equiv of 4-tolylboronic acid and adding additional equivalent(s) at 3 or 6 h intervals.  
This approach to arylboronic acid addition led to significantly higher yields of ketone 2b (64-
83%) and high enantioselectivities without a dramatic increase in the rate of 
protodeboronation. We chose to evaluate the scope of the conjugate addition reaction using 
the conditions identified in entry 10 as a practical combination of reactivity, 
enantioselectivity, and relative rates of productive versus unproductive reaction pathways.  
 
 
 
 
 
 
20 
 
Table 5. Identification of reaction conditions 
 
 
Entry temp (° C) X yield 2b (%)b yield 3a (%)c ee (%)d 
1 90 1 45 25 89 
2 80 1 42 10 89 
3 60 1 42 9 91 
4 40 1 24 6 94 
5e 60 1 49 10 91 
6e,f 60 1 55 12 92 
7f,g 60 2 70 11 91 
8 f,g 60 3 82 14 91 
9 f,h 60 3 64 9 91 
10 f,h 80 3 83 21 89 
aReaction conditions: 1a (1.0 equiv), Pd(TFA)2 (5 mol %), (S)-t-BuPyOx (6 mol %), 1,2-
dichloroethane (0.5 M), 3 h. bIsolated yields. cGC yield, calculated based on the total 
number of equiv of tolylboronic acid. dDetermined by chiral HPLC analysis. eReaction 
time = 6 h. f[1a] = 2 M. gAddition of 4-MeC6H4B(OH)2 at 6 h intervals. 
hAddition of 4-
MeC6H4B(OH)2 at 3 h intervals. 
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Scope of arylboronic acid:  
Studies to establish the scope of additions of a variety of arylboronic acids to 3-(4-
methoxyphenyl)-cyclohex-2-enone 1a are summarized in Scheme 3.  Additions of 
electronically diverse, para- and meta-substituted arylboronic acids occurred to generate the 
corresponding ketone products 2a-2j in 18-92% yields with 82-90% enantioselectivities. 
Additions of para-substituted electron-rich, electron-neutral, and halogenated arylboronic 
acids to 1a formed ketones 2a-e in moderate-to-high yields (49-92%) with high 
enantioselectivities (82-90% ee). However, the addition of electron-deficient 4-
trifluoromethylphenylboronic acid, which is less nucleophilic, generated 2f in only 38% 
yield. Additions of electron-rich meta-substituted arylboronic acids to 1a formed 2g and 2h 
in 60-88% yield with 89-90% ee.  In contrast, additions of meta- and ortho-halogenated 
arylboronic acids generate the corresponding ketones 2i-k in low yields (18-35%) but with 
good enantioselectivities (81-84% ee). 
These reactions also encompass additions of a variety of di- and tri-substituted 
arylboronic acids. The corresponding ketone products 2l-2p are generated in moderate-to-
good yields (36-67%) with good-to-high enantioselectivities (78-90%). However, additions 
of 2-methoxyphenylboronic acid, 3-furylboronic acid and 6-indolylboronic acid, which are 
more susceptible to protodeboronation, were unsuccessful under our reaction conditions.10 
22 
 
 
 
aReaction conditions: 1a (1 equiv), arylboronic acid (3 equiv), Pd(TFA)2 (10 mol %), (S)-t-
BuPyOx (12 mol %), 1,2-dichloroethane (2 M). bReaction run in the presence of 5 mol % of 
the palladium catalyst. cReaction performed in the presence of 5 equiv of water.  
 
Scheme 3. Enantioselective Pd-Catalyzed Conjugate Additions of Arylboronic Acids to 3-(4-
Methoxyphenyl)-cyclohex-2-enone 1aa 
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Scope of β-aryl β,β-disubstituted enones:  
To further expand the scope of these reactions, we studied additions of arylboronic 
acids to a variety of β-aryl β,β-disubstituted enones. These results are summarized in Scheme 
4. Additions of 4-tolylboronic acid to 3-arylcyclohex-2-enones containing electron-neutral, 
halogenated, electron-deficient, and electron-rich aryl groups generated 2q-2t in good yields 
(54-74%) with high enantioselectivities (87-93%). Successful formation of 2u demonstrates 
that this method allows access to products that are otherwise difficult to access when the 
same aryl unit is present in arylboronic acid. To demonstrate that meta-substituted 
arylboronic acids can be added to other enones, 3-methylphenylboronic acid was added to 3-
phenylcyclohex-2-enone to generate 2v in 76% yield with 86% ee. Addition of 
phenylboronic acid to 3-(4-methylphenyl)cyclohex-2-enone,  and 4-methoxyphenylboronic 
acid to 3-phenylcyclohex-2-enone generated enantiomers of 2q and 2b in 40-77% yield and 
81-88% ee. We then studied addition of 4-tolylboronic acid to cyclic enones with different 
ring sizes and to an acyclic enone. Addition of 4-tolylboronic acid to 3-(4-
methoxyphenyl)cyclopent-2-enone generated 2w in 60% yield and 91% ee. However, 
addition of 4-tolylboronic acid to 3-phenylcyclohept-2-enone and (E)-4-phenylpent-3-en-2-
one generated 2x and 2y in low yields (7-8%). Addition of 4-tolylboronic acid to 3-
pyridylcyclohex-2-enone was unsuccessful. In this reaction, 48% of total 4-tolylboronic acid 
underwent homocoupling to form 4,4ʹ-dimethyl-1,1ʹ-biphenyl 4a. The low yield likely results 
from catalyst deactivation by coordination of the pyridyl nitrogen of enone to the active 
catalyst.  
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aReaction conditions: 3-arylcyclohex-2-enone (1 equiv), arylboronic acid (3 equiv), 
Pd(TFA)2 (10 mol %), (S)-t-BuPyOx (12 mol %), 1,2-dichloroethane (2 M). 
bReaction 
performed in the presence of 5 equiv of water.  
 
Scheme 4. Enantioselective Pd-catalyzed conjugate additions of arylboronic acid to β-aryl 
β,β-disubstituted enonesa 
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Conclusion 
 
In conclusion, we have developed the first example of enantioselective, palladium-
catalyzed conjugate additions of arylboronic acids to β-aryl β,β-disubstituted cyclic enones. 
A palladium(II) catalyst generated in situ from Pd(TFA)2 and (S)-t-BuPyOx catalyzes 
enantioselective conjugate additions of electronically and structurally different arylboronic 
acids to a variety of β-aryl β,β-disubstituted enones. We have employed the strategy of 
iterative addition of arylboronic acid that leads to low rate of protodeboronation which 
allows additions of a wide array of arylboronic acids to a variety of enones in up to 92% 
yield and 93% enantioselectivity.  
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Experimental Details 
All reactions were conducted under air unless otherwise noted. Reactions involving 
air-sensitive reagents were conducted under inert atmosphere in a nitrogen-filled dry box or 
by standard Schlenk techniques. Moisture sensitive reaction were performed using glassware 
which were dried at 140 °C in an oven overnight prior to use. Flash column chromatography 
was performed on Siliflash® P60 silica gel (230-400 mesh) or using a Teledyne Isco 
Combiflash® Rf system with RediSep GoldTM columns using hexane/ethyl acetate mixtures 
as the eluent. Products were visualized on TLC by UV light and/or by staining with 2,4-
dinitrophenylhydrazine.   
HRMS (ESI) analysis was performed at the Iowa State Chemical Instrumentation 
Facility on an Agilent 6540 QTOF spectrometer. Optical rotations were measured on an 
Atago AP-300 automatic polarimeter. HPLC analyses were carried out on a Water Alliance 
HPLC system with an e2695 Separations Module and a 2489 (UV/Vis) dual wavelength 
detector. NMR spectra were acquired on Varian MR-400 and Bruker Avance III 600 
spectrometers at the Iowa State Chemical Instrumentation Facility.  Chemical shifts are 
reported relative to a residual solvent peak (CDCl3 = 7.26 ppm for 
1H, and 77.16 ppm for 
13C). 19F NMR shifts are reported based on indirect reference to CDCl3.
17 Coupling constants 
are reported in hertz. 
Materials 
 
3-(4-Methoxyphenyl)-cyclohex-2-enone 1a, 3-phenylcyclohex-2-enone 1b, 3-(4-
fluorophenyl)-cyclohex-2-enone 1c, 3-(4-methylphenyl)-cyclohex-2-enone 1d, 3-(4-
methoxyphenyl)-cyclopent-2-enone 1e, 3-(4-trifluoromethylphenyl)-cyclohex-2-enone 1f, 3-
(3-methoxyphenyl)-cyclohex-2-enone 1g, and 3-(2-methoxyphenyl)-cyclohex-2-enone 1h 
were prepared according to a literature procedure.18 Characterization data for 3-(4-
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methoxyphenyl)-cyclohex-2-enone 1a,19 3-phenylcyclohex-2-enone 1b,18 3-(4-fluorophenyl)-
cyclohex-2-enone 1c,20 3-(4-methylphenyl)-cyclohex-2-enone 1d,19  3-(4-methoxyphenyl)-
cyclopent-2-enone 1e,21 3-(4-trifluoromethylphenyl)-cyclohex-2-enone 1f,22 3-(3-
methoxyphenyl)-cyclohex-2-enone 1g,20 and 3-(2-methoxyphenyl)-cyclohex-2-enone 1h20 
matched previously reported data. 3-(3-Pyridyl)-cyclohex-2-enone 1i,23 (E)-4-
phenylcyclohept-2-enone 1j,22 (E)-4-phenylpent-3-en-2-one 1k24 were synthesized according 
to reported literature procedures. (4R,4'R)-2,2'-(propane-2,2-diyl)bis(4-phenyl-4,5-
dihydrooxazole) ((R)-PhBox),25 (S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole ((S)-t-
BuPyOx),26 and (S)-4-isopropyl-2-(pyridin-2-yl)-4,5-dihydrooxazole ((S)-i-PrPyOx)27 were  
prepared according to previously reported literature procedures. Palladium trifluoroacetate, 
(4S,4'S)-2,2'-(propane-2,2-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole) ((S)-t-BuBox), 3,5-
dimethylphenylboronic acid and 2,4-dinitrophenylhydrazine were purchased from Sigma-
Aldrich and used without further purification. 2,2´-Bipyridine was purchased from Fisher 
Scientific and used without further purification. 4-Methylphenylboronic acid, phenylboronic 
acid, 4-methoxyphenylboronic acid, 4-fluorophenylboronic acid, 3-methoxyphenylboronic 
acid, 3-chlorophenylboronic acid, 3-fluorophenylboronic acid, 2-fluorophenylboronic acid 
and 4-trifluoromethylphenylbromide were purchased from AK Scientific and used without 
further purification. 4-Biphenylboronic acid, 4-trifluoromethylphenylboronic acid, 2-
methoxyphenylboronic acid, 3-fluoro-4-methoxyphenylboronic acid, 3,4-
methylenedioxyphenylboronic acid, 3,4-dimethylphenylboronic acid, 3,4,5-
trimethoxyphenylboronic acid, 2-furanylboronic acid and 6-indolylboronic acid were 
purchased from Frontier Scientific, Inc. and used without further purification. 4-
Chlorophenylboronic acid was purchased from Combi-Blocks, Inc. and used without further 
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purification. 3-Methylphenylboronic acid was purchased from Ark Pharm, Inc. and used 
without further purification. Dibromomethane was purchased from Acros and used without 
further purification.  
 
 
General Procedure A: Pd-Catalyzed Conjugate Additions of Arylboronic Acids to β-
Aryl, β, β-Disubstituted Enones to Access Racemic Ketones 2a-2w 
 
 
 
To a 1 dram vial were added Pd(TFA)2 (10 mg, 0.030 mmol), 2,2´-bipyridine (5.6 mg, 0.036 
mmol), the appropriate enone (0.300 mmol), arylboronic acid (1.20 mmol, 4.00 equiv) and 
50 mM aqueous sodium trifluoroacetate solution (0.10 mL, pH = 8.2). The vial was sealed 
with a PTFE/silicone-lined septum cap. The reaction mixture was then stirred at 100 °C for 
24 h. The reaction mixture was filtered through a short plug of magnesium sulfate (top) and 
silica gel (bottom) (eluting with 20 mL of ethyl acetate) and then concentrated under 
vacuum. The crude reaction mixture was dissolved in CDCl3 (1 mL) and CH2Br2 (10.5 µL, 
0.150 mmol) was added as an internal standard. NMR yields were determined by 1H NMR 
spectroscopy of the crude reaction mixture. The crude reaction mixture was purified by flash 
column silica gel chromatography or using a Teledyne Isco Combiflash® Rf system with 
RediSep GoldTM columns (hexane:ethyl acetate) to give corresponding ketones. Racemic 
ketones 2a-2w were isolated in 18-85% yield. 
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Table S1. Catalyst Identification for Pd-catalyzed Conjugate Additions of 
Phenylboronic Acid to 3-(4-Methoxyphenyl)-cyclohex-2-enone 1aa  
 
O
O
O
O
PhB(OH)2 (4 equiv)
Pd(TFA)2 (5 mol %)
Ligand (6 mol %)
Solvent, temperature
 24 h
O
N N
O
N
N
O
(S)-t-BuPyOx
N
N
O
(S)-i-PrPyOx
O
N N
O
(R)-PhBox (S)-t-BuBox  
Entry temp (°C) ligand solvent productb % eec 
1 80 (R)-PhBox aq. NaTFA (pH = 8.2) 0 - 
2 80 (S)-t-BuBox aq. NaTFA (pH = 8.2) 0 - 
3 80 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 17 77 
4 80 (S)-i-PrPyOx aq. NaTFA (pH = 8.2) 21 49 
5 100 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 8d - 
6 60 (S)-t-BuPyOx aq. NaTFA (pH = 8.2) 4 71 
7 80 (S)-t-BuPyOx 1,2-dichloroethane 34 88 
8e 80 (S)-t-BuPyOx 1,2-dichloroethane 34 91 
9e 80 (S)-t-BuPyOx methanol 36 84 
10e, f 80 (S)-t-BuPyOx 1,2-dichloroethane 30 91 
11e 90 (S)-t-BuPyOx 1,2-dichloroethane 39 91 
aReaction conditions: 3-(4-methoxyphenyl)-cyclohex-2-enone 1a (0.300 mmol), 
phenylboronic acid (1.20 mmol), Pd(TFA)2 (0.015 mmol), ligand (0.018 mmol), solvent (0.1 
mL), 24 h. bIsolated yield. cDetermined by chiral HPLC analysis. dYield determined by 1H 
NMR using dibromomethane as an internal standard. eReaction run in 0.6 mL of solvent. 
fReaction run in the presence of 30 mol % NH4PF6 and 5 equiv. of water. 
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General Procedure B: Catalyst Identification by Conjugate Addition of Phenylboronic 
Acid to 3-(4-Methoxyphenyl)-cyclohex-2-enone 1a 
 
To a 1 dram vial were added Pd(TFA)2 (5.0 mg, 0.015 mmol), ligand (0.018 mmol), 3-(4-
methoxyphenyl)-cyclohex-2-enone 1a (60.7 mg, 0.300 mmol), phenylboronic acid (146 mg, 
1.20 mmol), and solvent (0.1 mL). The vial was sealed with a PTFE/silicone-lined septum 
cap. The reaction mixture was then stirred at 60-100 °C for 24 h. The reaction mixture was 
filtered through a short plug of magnesium sulfate (top) and silica gel (bottom) (eluting with 
20 mL of ethyl acetate) and then concentrated under vacuum. The crude reaction mixture was 
dissolved in CDCl3 (1 mL) and CH2Br2 (10.5 µL, 0.15 mmol) was added as an internal 
standard. NMR yields were determined by 1H NMR spectroscopy of the crude reaction 
mixture. The crude product was purified by silica gel column chromatography with a 
CombiFlash system (4 g column, 100:0 to 90:10 hexane: EtOAc) to give 2b as a colorless oil. 
The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 21.1 min 
(minor); tR 34.8 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., 
Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min].  
 
General Procedure C: Enantioselective, Pd-Catalyzed Conjugate Additions of 
Arylboronic Acids to β-Aryl, β,β-Disubstituted Enones to Access Ketones 2a-2y 
 
Ar2B(OH)2
Pd(TFA)2 (5-10 mol %)
(S)-t-BuPyOx (6-12 mol %)
Ar1
O
n
Ar1
O
n
Ar2
n = 0, 1, 2 n = 0, 1, 2
1,2-dichloroethane
80 °C, 9 h
1a-1k 2a-2y  
 
To a 1 dram vial were added Pd(TFA)2 (10 mg, 0.030 mmol), (S)-t-BuPyOx (7.4 mg, 0.036 
mmol), the appropriate enone (0.300 mmol), arylboronic acid (0.300 mmol, 1.00 equiv) and 
1,2-dichloroethane (0.15 mL). The vial was sealed with a PTFE/silicone-lined septum cap. 
The reaction mixed was then stirred at 80 °C for 3 h. After 3 h, another equivalent of 
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arylboronic acid (0.300 mmol, 1.00 equiv) was added and the reaction mixture was stirred for 
another 3 h. The same procedure was followed for a third equiv of arylboronic acid (0.300 
mmol, 1.00 equiv). The reaction mixture was filtered through a short plug of silica gel 
(eluting with 20 mL of ethyl acetate) and then concentrated under vacuum. The crude 
reaction mixture was dissolved in CDCl3 (1 mL) and CH2Br2 (10.5 µL, 0.15 mmol) was 
added as an internal standard. NMR yields were determined by 1H NMR spectroscopy of the 
crude reaction mixture. The crude reaction mixture was purified by flash column silica gel 
chromatography or using a Teledyne Isco Combiflash® Rf system with RediSep GoldTM 
columns (hexane: ethyl acetate) to yield the corresponding ketone. Note: for synthesis of 
ketones 2a and 2b, Pd(TFA)2 (5.0 mg, 0.015 mmol) and (S)-t-BuPyOx (3.7 mg, 0.018 mmol) 
were used to generate the catalyst.  
 
Characterization Data for Ketones 2a-2w 
(S)-3-(4-methoxyphenyl)-3-(p-tolyl)cyclohexan-1-one (2a): Prepared 
according to General Procedure C from 3-(4-methoxyphenyl)cyclohex-2-en-1-
one 1a (60.7 mg, 0.300 mmol) and 4-tolylphenylboronic acid (122 mg, 0.900 
mmol) using palladium trifluoroacetate (5.0 mg, 0.015 mmol) and (S)-t-BuPyOX (3.7 mg, 
0.018 mmol). The crude product was purified by flash chromatography (90:10 hexane: 
EtOAc) to give 2a (72.4 mg, 0.246 mmol, 83%) as a colorless oil. The enantiomeric excess 
was determined by HPLC analysis (220 nm, 25 °C) tR 34.2 min (minor); tR 40.8 min (major) 
[Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 
1.0 mL/min] to be 89% ee. [α]D22 = +10.2° (c 0.78, CHCl3). 1H NMR (400 MHz, CDCl3): δ 
1.65-1.74 (m, 2H), 2.30 (s, 3H), 2.34 (t, J = 6.8 Hz, 2H), 2.52 (d, J = 7.2 Hz, 1H), 2.53 (d, J 
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= 7.2 Hz, 1H), 2.90 (d, J = 15.6 Hz, 1H), 2.94 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 6.81 (ddd, J 
= 8.8, 3.2, 2.0 Hz, 2H), 7.08 (s, 4H), 7.12 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H). 13C NMR (101 
MHz, CDCl3): δ 21.0, 21.3, 36.0, 40.9, 49.6, 54.1, 55.3, 113.8, 126.9, 128.1, 129.2, 135.8, 
129.6, 144.8, 157.9, 211.1. HRMS (ESI): Calcd. for C20H23O2
+ ([M+H]+): 295.1693 Found: 
295.1689. 
 
(S)-3-(4-methoxyphenyl)-3-phenylcyclohexan-1-one (2b): Prepared according 
to General Procedure C from 3-(4-methoxyphenyl)cyclohex-2-en-1-one 1a 
(60.7 mg, 0.300 mmol) and phenylboronic acid (110 mg, 0.900 mmol) using 
palladium trifluoroacetate (5.0 mg, 0.015 mmol) and (S)-t-BuPyOX (3.7 mg, 0.018 mmol). 
The crude product was purified with a CombiFlash system (4 g column, 100:0 to 90:10 
hexane: EtOAc) to give 2b (58.8 mg, 0.210 mmol, 70%) as a colorless oil. The enantiomeric 
excess was determined by HPLC analysis (220 nm, 25 °C) tR 21.1 min (minor); tR 34.8 min 
(major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 
80:20, 1.0 mL/min] to be 87% ee. [α]D26 = +17.5 (c 0.80, CHCl3). 1H NMR (400 MHz, 
CDCl3): δ 1.66-1.72 (m, 2H), 2.35 (t, J = 6.8 Hz, 2H), 2.55 (d, J = 7.2 Hz, 1H), 2.56 (d, J = 
7.2 Hz, 1H), 2.91 (d, J = 15.6 Hz, 1H), 2.96 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 6.81 (d, J = 
8.8 Hz, 2H), 7.12 (d, J = 8.8 Hz, 2H), 7.17 (t, J = 7.2 Hz, 1H), 7.20 (d, J = 7.2 Hz, 2H), 7.27 
(t, J = 7.2 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.2, 35.9, 40.9, 49.9, 54.0, 55.3, 113.8, 
126.3, 127.0, 128.2, 128.5, 139.4, 147.8, 157.9, 211.0. HRMS (ESI): Calcd. for C19H21O2
+ 
([M+H]+): 281.1536 Found: 281.1539.  
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(S)-3-([1,1'-biphenyl]-4-yl)-3-(4-methoxyphenyl)cyclohexan-1-one (2c): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and [1,1'-
biphenyl]-4-ylboronic acid (178 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2c (98.4 mg, 0.276 
mmol, 92%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 25.3 min (minor); tR 29.7 min (major) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 90% ee. [α]D26 = 
+11.0° (c 0.73, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.66-1.81 (m, 2H), 2.38 (t, J = 6.8 
Hz, 2H), 2.54-2.64 (m, 2H), 2.97 (d, J = 15.2, 1H), 3.01 (d, J = 15.2, 1H), 3.79 (s, 3H), 6.86 
(ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 7.19 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 
7.34 (td, J = 8.4, 7.2 Hz, 1H), 7.44 (dd, J = 8.4, 7.2 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.58 
(d, J = 7.2 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.3, 36.0, 40.9, 49.8, 54.0, 55.3, 113.9, 
127.1, 127.2, 127.3, 127.4, 128.2, 128.9, 139.0, 139.2, 140.6, 146.8, 157.9, 210.9. HRMS 
(ESI): Calcd. for C25H25O2
+ ([M+H]+): 357.1849 Found: 357.1826. 
 
(R)-3-(4-chlorophenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2d): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 4-
chlorophenylboronic acid (141 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2d (51.9 mg, 0.165 
mmol, 55%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 19.4 min (minor); tR 36.6 min (major) [Chiracel AS-H (0.46 cm x 25 cm) 
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(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 83% ee. [α]D22 = 
+8.0° (c 1.00, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.65-1.71 (m, 2H), 2.34 (t, J = 6.4 Hz, 
2H), 2.50-2.53 (m, 2H), 2.86 (d, J = 15.2 Hz, 1H), 2.92 (d, J = 15.2 Hz, 1H), 3.77 (s, 3H), 
6.81 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 
Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.2, 35.9, 40.8, 49.6, 53.9, 55.3, 114.0, 128.1, 
128.4, 128.6, 132.1, 138.8, 146.3, 158.0, 210.6. HRMS (ESI): Calcd. for C19H20ClO2
+ 
([M+H]+): 315.1146 Found: 315.1138. 
 
(R)-3-(4-fluorophenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2e): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 4-
fluorophenylboronic acid (126 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2e (43.9 mg, 0.147 
mmol, 49%) as a colorless oil with approximately 5% (calculated by 1H NMR spectroscopy) 
of 4'-methoxy-3-methyl-1,1'-biphenyl as an inseparable impurity. The enantiomeric excess 
was determined by HPLC analysis (220 nm, 25 °C) tR 22.9 min (minor); tR 44.7 min (major) 
[Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 
1.0 mL/min] to be 91% ee. [α]D26 = +23.1° (c 0.61, CHCl3) 1H NMR (400 MHz, CDCl3): δ 
1.65-1.71 (m, 2H), 2.34 (t, J = 6.4 Hz, 2H), 2.51 (d, J = 7.2 Hz, 1H), 2.52 (d, J = 7.2 Hz, 1H), 
2.87 (d, J = 15.2 Hz, 1H), 2.93 (d, J = 15.2 Hz, 1H), 3.77 (s, 3H), 6.81 (d, J = 8.4 Hz, 2H), 
6.94 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.4 
Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 21.2, 36.1, 40.8, 49.6, 
54.2, 55.3, 114.0, 115.3 (d, J = 21.1 Hz, 2C), 128.1, 128.6 (d, J = 7.9 Hz, 2C), 139.2, 143.5 
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(d, J = 3.3 Hz, 1C), 158.0, 161.2 (d, J = 246.6 Hz, 1C), 162.4, 210.7. 19F NMR (376 MHz, 
CDCl3): δ -116.9 (m, 1F). HRMS (ESI): Calcd. for C19H20FO2+ ([M+H]+): 299.1442 Found: 
299.1438. 
 
(S)-3-(4-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)cyclohexan-1-one 
(2f): Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 4-
trifluoromethylphenylboronic acid (171 mg, 0.900 mmol). The crude product was purified 
with a CombiFlash system (4 g column, 100:0 to 90:10 hexane: EtOAc) to give 2f (39.7 mg, 
0.114 mmol, 38%) as a colorless oil. The enantiomeric excess was determined by HPLC 
analysis (220 nm, 25 °C) tR 23.2 min (minor); tR 27.3 min (major) [Chiracel OJ-H (0.46 cm x 
25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 82% ee. 
[α]D19 = +12.3° (c 0.98, CHCl3) 1H NMR (400 MHz, CDCl3): δ 1.66-173 (m, 2H), 2.31-2.42 
(m, 2H), 2.56 (d, J = 8.0 Hz, 1H), 2.57 (d, J = 8.0 Hz, 1H), 2.89 (d, J = 15.2 Hz, 1H), 2.97 (d, 
J = 15.2 Hz, 1H), 3.78 (s, 3H), 6.82 (ddd, J = 8.8, 3.6, 2.0 Hz, 2H), 7.09 (ddd, J = 8.8, 3.6, 
2.0 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H). 13C NMR (151 MHz, 
CDCl3): δ 21.2, 35.9, 40.8, 50.1, 53.8, 55.4, 114.1, 123.7 (q, J = 238.0 Hz, 1C), 125.6 (q, J = 
5.6 Hz, 1C), 127.4, 128.2, 128.6 (q, J = 48.9 Hz, 1C), 138.4, 151.9, 158.2, 210.3. 19F NMR 
(376 MHz, CDCl3): δ -62.5 (s, 3F). HRMS (ESI): Calcd. for C20H20F3O2+ ([M+H]+): 
349.1410 Found: 349.1385. 
 
(R)-3-(4-methoxyphenyl)-3-(m-tolyl)cyclohexan-1-one (2g): Prepared 
according to General Procedure C from 3-(4-methoxyphenyl)cyclohex-2-en-1-
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one 1a (60.7 mg, 0.300 mmol) and 3-tolylboronic acid (122 mg, 0.900 mmol). The crude 
product was purified with a CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) 
to give 2g (77.7 mg, 0.264 mmol, 88%) as a colorless oil. The enantiomeric excess was 
determined by HPLC analysis (220 nm, 25 °C) tR 21.1 min (minor); tR 25.8 min (major) 
[Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 
1.0 mL/min] to be 90% ee.  [α]D22 = +126.3° (c 0.97, CHCl3). 1H NMR (400 MHz, CDCl3): δ 
1.62-1.74 (m, 2H), 2.29 (s, 3H), 2.34 (t, J = 6.4 Hz, 2H), 2.48-2.58 (m, 2H), 2.89 (d, J = 15.6 
Hz, 1H), 2.94 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 6.81 (d, J = 7.2 Hz, 2H), 6.99 (d, J = 7.2 Hz, 
2H), 7.00 (s, 1H), 7.12 (d, J = 7.2 Hz, 2H), 7.16 (t, J = 7.2 Hz, 1H). 13C NMR (101 MHz, 
CDCl3): δ 21.2, 21.8, 35.9, 40.9, 49.8, 54.0, 55.3, 113.8, 124.1, 127.0, 127.6, 128.2, 128.4, 
138.0, 139.5, 147.7, 157.8, 211.1. HRMS (ESI): Calcd. for C20H23O2
+ ([M+H]+): 295.1693 
Found: 295.1694. 
 
(R)-3-(3-methoxyphenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2h): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 3-
methoxyphenylboronic acid (137 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 90:10 hexane: EtOAc) to give 2h (55.9 mg, 0.180 
mmol, 60%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 42.5 min (major); tR 63.9 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 90% ee. [α]D26 = 
+10.2° (c 0.79, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.61-1.76 (m, 2H), 2.34 (t, J = 6.8 
Hz, 2H), 2.51 (d, J = 6.0 Hz, 1H), 2.53 (d, J = 6.0 Hz, 1H), 2.89 (d, J = 15.2 Hz, 1H), 2.94 (d, 
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J = 15.2 Hz, 1H), 3.74 (s, 3H), 3.77 (s, 3H), 6.71 (dd, J = 7.6, 2.0 Hz, 1H), 6.75-6.82 (m, 
4H), 7.12 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 7.19 (t, J = 8.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3): δ 21.2, 35.9, 40.8, 49.9, 54.0, 55.2, 55.3, 111.0, 113.5, 113.8, 119.4, 128.1, 129.5, 
139.2, 149.5, 157.9, 159.6, 210.9. HRMS (ESI): Calcd. for C20H23O3
+ ([M+H]+): 311.1642 
Found: 311.1649.  
 
(R)-3-(3-chlorophenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2i): Prepared 
according to General Procedure C from 3-(4-methoxyphenyl)cyclohex-2-en-1-
one 1a (60.7 mg, 0.300 mmol) and 3-chlorophenylboronic acid (141 mg, 0.900 
mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 to 
90:10 hexane: EtOAc) to give 2i (33.1 mg, 0.105 mmol, 35%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 18.1 min (minor); 
tR 29.7 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 80:20, 1.0 mL/min] to be 85% ee. [α]D26 = +35.4° (c 0.57, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ 1.60-1.77 (m, 2H), 2.35 (t, J = 6.8 Hz, 2H), 2.47-2.57 (m, 2H), 2.85 (d, 
J = 15.2 Hz, 1H), 2.96 (d, J = 15.2 Hz, 1H), 3.78 (s, 3H), 6.82 (ddd, J = 9.2, 3.2, 2.4 Hz, 2H), 
7.07 (ddd, J = 7.6, 2.4, 1.2 Hz, 1H), 7.09 (ddd, J = 9.2, 3.2, 2.4 Hz, 2H), 7.15 (ddd, J = 7.6, 
2.4, 1.2 Hz, 1H), 7.16-7.22 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 21.2, 35.9, 40.8, 49.9, 
53.8, 55.3, 114.0, 125.3, 126.6, 127.1, 128.2, 129.8, 134.5, 138.4, 150.1, 158.1, 210.4. 
HRMS (ESI): Calcd. for C19H20ClO2
+ ([M+H]+): 315.1146 Found: 315.1138. 
 
(R)-3-(3-fluorophenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2j): Prepared 
according to General Procedure C from 3-(4-methoxyphenyl)cyclohex-2-en-1-
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one 1a (60.7 mg, 0.300 mmol) and 3-fluorophenylboronic acid (126 mg, 0.900 mmol). The 
crude product was purified was purified with a CombiFlash system (4 g column, 100:0 to 
95:5 hexane: EtOAc) to give 2j (16.1 mg, 0.054 mmol, 35%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 21.1 min (minor); 
tR 29.6 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 80:20, 1.0 mL/min] to be 84% ee. [α]D21 = -319.2° (c 0.31, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ 1.65-1.76 (m, 2H), 2.35 (t, J = 6.8 Hz, 2H), 2.47-2.57 (m, 2H), 2.87 (d, 
J = 15.2 Hz, 1H), 2.95 (d, J = 15.2 Hz, 1H), 3.77 (s, 3H), 6.82 (ddd, J = 8.4, 3.2, 2.4 Hz, 2H), 
6.83-6.91 (m, 2H), 6.97-7.00 (m, 1H), 7.10 (ddd, J = 8.4, 3.2, 2.4 Hz, 2H), 7.20-7.25 (m, 
1H). 13C NMR (151 MHz, CDCl3): δ 21.2, 36.0, 40.9, 49.9 (d, J = 1.4 Hz, 1C), 53.9, 55.4, 
113.3 (d, J = 21.1 Hz, 1C), 114.1, 114.2 (d, J = 20.1 Hz, 1C), 122.7 (d, J = 2.6 Hz, 1C), 
128.2, 130.0 (d, J = 8.3 Hz, 1C), 138.6, 150.7 (d, J = 6.5 Hz, 1C), 158.2, 163.1 (d, J = 245.7 
Hz, 1C), 210.4. 19F NMR (376 MHz, CDCl3): δ -112.5 (m, 1F). HRMS (ESI): Calcd. for 
C19H20FO2
+ ([M+H]+): 299.1442 Found: 299.1446. 
 
(R)-3-(2-fluorophenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2k): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 2-
fluorophenylboronic acid (126 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2k (20.6 mg, 0.069 
mmol, 23%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 39.4 min (major); tR 45.6 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 75:25, 1.0 mL/min] to be 81% ee. [α]D21 = 
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-173.2° (c 0.64, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.57-1.67 (m, 1H), 1.69-1.79 (m, 
1H), 2.36 (t, J = 6.8 Hz, 2H), 2.47 (ddd, J = 12.4, 9.2, 2.4 Hz, 1H), 2.75 (ddd, J = 12.4, 9.2, 
2.4 Hz, 1H), 2.94 (d, J = 15.6 Hz, 1H), 3.01 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 6.81 (ddd, J = 
8.8, 3.2, 2.0 Hz, 2H), 6.91 (ddd, J = 8.0, 4.4, 1.2 Hz, 1H), 7.09-7.14 (m, 3H), 7.19 (m, 1H), 
7.40 (td, J = 8.4, 2.0 Hz, 1H). 13C NMR (151 MHz, CDCl3): δ 21.2, 34.5 (d, J = 3.5 Hz, 1C), 
41.0, 48.6 (d, J = 1.2 Hz, 1C), 53.2 (d, J = 2.1 Hz, 1C), 55.3, 113.8, 116.9 (d, J = 23.3 Hz, 
1C), 124.1 (d, J = 3.5 Hz, 1C), 127.6, 128.4 (d, J = 4.4 Hz, 1C), 128.8 (d, J = 8.9 Hz, 1C), 
134.3 (d, J = 10.4 Hz, 1C), 138.5, 158.0, 160.8 (d, J = 249.5 Hz, 1C), 210.8. 19F NMR (376 
MHz, CDCl3): δ -108.5 (m, 1F). HRMS (ESI): Calcd. for C19H20FO2+ ([M+H]+): 299.1442 
Found: 299.1441. 
 
(R)-3-(3-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)cyclohexan-1-one 
(2l): Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 3-
fluoro-4-methoxyphenylboronic acid (153 mg, 0.900 mmol). The crude product was with a 
CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2l (65.0 mg, 0.198 
mmol, 66%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 40.2 min (major); tR 53.3 min (minor) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 88% ee. [α]D26 = 
+2.2° (c 0.90, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.65-1.71 (m, 2H), 2.33 (t, J = 6.8 Hz, 
2H), 2.43-2.54 (m, 2H), 2.85 (d, J = 15.6 Hz, 1H), 2.90 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 
3.84 (s, 3H), 6.81 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 6.83-6.90 (m, 2H), 6.92 (ddd, J = 8.4 2.4, 
0.8 Hz, 1H), 7.09 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.2, 36.0, 
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40.8, 49.3 (d, J = 1.7 Hz, 1C), 54.0, 55.3, 56.3, 113.0 (d, J = 2.1 Hz, 1C), 113.9, 115.0 (d, J = 
19.0 Hz, 1C), 122.5 (d, J = 3.3 Hz, 1C), 128.0, 138.9, 140.9 (d, J = 5.1 Hz, 1C), 145.9 (d, J = 
10.8 Hz, 1C), 152.2 (d, J = 246.8 Hz, 1C), 157.9, 210.6. 19F NMR (376 MHz, CDCl3): δ -
134.4 (m, 1F). HRMS (ESI): Calcd. for C20H22FO3
+ ([M+H]+): 329.1547 Found: 329.1553. 
 
(R)-3-(benzo[d][1,3]dioxol-5-yl)-3-(4-methoxyphenyl)cyclohexan-1-one 
(2m): Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 
benzo[d][1,3]dioxol-5-ylboronic acid (149 mg, 0.900 mmol). The crude product was purified 
with a CombiFlash system (4 g column, 100:0 to 95:5 hexane: EtOAc) to give 2m (42.8 mg, 
0.132 mmol, 44%) as a colorless oil. The enantiomeric excess was determined by HPLC 
analysis (220 nm, 25 °C) tR 22.8 min (minor); tR 36.2 min (major) [Chiracel AS-H (0.46 cm x 
25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 90% ee. 
[α]D26 = +16.3° (c 0.74, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.63-1.73 (m, 2H), 2.33 (t, J 
= 6.8 Hz, 2H), 2.42-2.53 (m, 2H), 2.87 (s, 2H), 3.77 (s, 3H), 5.89 (s, 2H), 6.59-6.60 (m, 1H), 
6.71 (m, 2H), 6.81 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 7.11 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H). 13C 
NMR (101 MHz, CDCl3): δ 21.2, 36.1, 40.8, 49.7, 54.3, 55.3, 101.1, 107.8, 107.9, 113.9, 
119.9, 128.0, 139.5, 141.8, 145.9, 148.0, 157.9, 210.9. HRMS (ESI): Calcd. for C20H21O4
+ 
([M+H]+): 325.1434 Found: 325.1424.  
 
(R)-3-(3,4-dimethylphenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2n): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 3,4-
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dimethylphenylboronic acid (135 mg, 0.900 mmol). The crude product was purified by flash 
chromatography (90:10 hexane: EtOAc) to give 2n (33.3 mg, 0.108 mmol, 36%) as a 
colorless oil. The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 
18.6 min (minor); tR 68.8 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 85% ee. [α]D22 = -94.4° (c 
0.98, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.61-1.76 (m, 2H), 2.20 (s, 6H), 2.33 (t, J = 
6.8 Hz, 2H), 2.47-2.57 (m, 2H), 2.89 (d, J = 15.2 Hz, 1H), 2.94 (d, J = 15.2 Hz, 1H), 3.77 (s, 
3H), 6.82 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H), 6.91-6.94 (m, 2H), 7.03 (d, J = 8.0 Hz, 1H), 7.12 
(ddd, J = 8.8, 3.2, 2.0 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 19.4, 20.2, 21.3, 36.0, 40.9, 
49.5, 54.1, 55.3, 113.8, 124.4, 128.16, 128.20, 129.7, 134.5, 136.6, 139.6, 142.2, 157.8, 
211.2. HRMS (ESI): Calcd. for C21H25O2
+ ([M+H]+): 309.1849 Found: 309.1846.   
 
(R)-3-(3,5-dimethylphenyl)-3-(4-methoxyphenyl)cyclohexan-1-one (2o): 
Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 3,5-
dimethylphenylboronic acid (135 mg, 0.900 mmol). The crude product was purified by flash 
chromatography (90:10 hexane: EtOAc) to give 2o (35.2 mg, 0.114 mmol, 38%) as a 
colorless oil. The enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 
19.8 min (minor); tR 22.4 min (major) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 90:10, 1.0 mL/min] to be 90% ee. [α]D26 = -6.1° (c 0.66, 
CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.60-1.76 (m, 2H), 2.25 (s, 6H), 2.33 (t, J = 6.8 Hz, 
2H), 2.47-2.57 (m, 2H), 2.88 (d, J = 15.6 Hz, 1H), 2.93 (d, J = 15.2 Hz, 1H), 3.78 (s, 3H), 
6.79-6.83 (m, 5H), 7.12 (ddd, J = 8.8, 3.2, 2.0 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.3, 
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21.7, 36.0, 40.9, 49.7, 54.1, 55.3, 113.8, 124.8, 128.0, 128.2, 137.9, 139.6, 147.7, 157.8, 
211.1. HRMS (ESI): Calcd. for C21H25O2
+ ([M+H]+): 309.1849 Found: 309.1848.   
 
(R)-3-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)cyclohexan-1-one 
(2p): Prepared according to General Procedure C from 3-(4-
methoxyphenyl)cyclohex-2-en-1-one 1a (60.7 mg, 0.300 mmol) and 3,4,5-
trimethoxyphenylboronic acid (191 mg, 0.900 mmol). The crude product was purified with a 
CombiFlash system (4 g column, 100:0 to 98:2 hexane: EtOAc) to give 2p (74.5 mg, 0.201 
mmol, 67%) as a colorless oil. The enantiomeric excess was determined by HPLC analysis 
(220 nm, 25 °C) tR 22.8 min (minor); tR 36.2 min (major) [Chiracel AS-H (0.46 cm x 25 cm) 
(from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 80:20, 1.0 mL/min] to be 78% ee. [α]D20 = 
-33.7° (c 1.07, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.62-1.75 (m, 2H), 2.34 (t, J = 6.4 
Hz, 2H), 2.45-2.56 (m, 2H), 2.85 (d, J = 15.6 Hz, 1H), 2.94 (d, J = 15.2 Hz, 1H), 3.76 (s, 
6H), 3.77 (s, 3H), 3.81 (s, 3H), 6.39 (s, 2H), 6.81 (d, J = 8.8 Hz, 2H), 7.12 (d, J = 8.8 Hz, 
2H). 13C NMR (101 MHz, CDCl3): δ 21.3, 36.2, 40.9, 50.3, 54.4, 55.3, 56.2, 60.9, 104.7, 
113.8, 127.9, 136.3, 139.5, 143.1, 153.0, 158.0, 211.0. HRMS (ESI): Calcd. for C22H27O5
+ 
([M+H]+): 325.1434 Found: 325.1436. 
 
 (R)-3-phenyl-3-(p-tolyl)cyclohexan-1-one (2q): Prepared according to 
General Procedure C from 3-phenylcyclohex-2-en-1-one 1b (51.6 mg, 0.300 
mmol) and 4-methylphenylboronic acid (122 mg, 0.900 mmol). The crude 
product was purified by flash chromatography (90:10 hexane: EtOAc) to give (R)-2q (55.5 
mg, 0.210 mmol, 70%) as a colorless oil. The enantiomeric excess was determined by HPLC 
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analysis (220 nm, 25 °C) tR 48.9 min (minor); tR 57.8 min (major) [Chiracel AS-H (0.46 cm x 
25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:01, 1.0 mL/min] to be 87% ee. 
[α]D22 = -3.7 (c 1.09, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.66-1.72 (m, 2H), 2.30 (s, 
3H), 2.35 (t, J = 6.4 Hz, 2H), 2.55-2.58 (m, 2H), 2.92 (d, J = 15.2 Hz, 1H), 2.98 (d, J = 15.2 
Hz, 1H), 7.06-7.11 (m, 4H), 7.15-7.22 (m, 3H), 7.25-7.29 (m, 2H). 13C NMR (101 MHz, 
CDCl3): δ 21.0, 21.2, 35.9, 40.9, 50.2, 53.9, 126.3, 126.96, 127.01, 128.5, 129.3, 135.9, 
144.4, 147.6, 210.9. HRMS (ESI): Calcd. for C19H21O
+ ([M+H]+): 265.1587 Found: 
265.1593. 
 
 (S)-3-(4-fluorophenyl)-3-(p-tolyl)cyclohexan-1-one (2r): Prepared 
according to General Procedure C from 3-(4-fluorophenyl)-cyclohex-2-en-1-
one 1c (57.0 mg, 0.300 mmol) and 4-methylphenylboronic acid (122 mg, 0.900 
mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 to 
90:10 hexane: EtOAc) to give 2r (62.7 mg, 0.222 mmol, 74%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 36.8 min (major); 
tR 50.4 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 99:01, 1.0 mL/min] to be 89% ee. [α]D22 = +124.1° (c 1.05, CHCl3). 1H 
NMR (400 MHz, CDCl3): δ 1.63-1.74 (m, 2H), 2.30 (s, 3H), 2.35 (t, J = 6.8 Hz, 2H), 2.49-
2.59 (m, 2H), 2.90 (d, J = 15.2 Hz, 1H), 2.92 (d, J = 15.2 Hz, 1H), 6.94 (ddd, J = 8.8, 3.2, 2.0 
Hz, 1H), 6.96 (ddd, J = 8.8, 3.2, 2.0 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 
2H), 7.16 (ddd, J = 8.8, 3.2, 2.0 Hz, 1H), 7.18 (ddd, J = 8.8, 3.2, 2.0 Hz, 1H). 13C NMR (101 
MHz, CDCl3): δ 21.0, 21.2, 36.0, 40.8, 49.8, 54.0, 115.3 (d, J = 21.2 Hz, 1C), 126.8, 128.6 
(d, J = 7.9 Hz, 1C), 129.3, 136.1, 143.4 (d, J = 3.3 Hz, 2C), 144.2, 160.0 (d, J = 246.6 Hz, 
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2C), 210.7. 19F NMR (376 MHz, CDCl3): δ -116.8 (m, 1F). HRMS (ESI): Calcd. for 
C19H20FO
+ ([M+H]+): 283.1493 Found: 283.1496. 
 
 (S)-3-(p-tolyl)-3-(4-(trifluoromethyl)phenyl)cyclohexan-1-one (2s): 
Prepared according to General Procedure C from 3-(4-trifluoromethylphenyl)-
cyclohex-2-en-1-one 1f (72.1 mg, 0.300 mmol) and 4-methylphenylboronic 
acid (122 mg, 0.900 mmol). The crude product was purified with a CombiFlash system (4 g 
column, 100:0 to 90:10 hexane: EtOAc) to give 2s (53.8 mg, 0.162 mmol, 54%) as a 
colorless oil. The enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 
37.0 min (major); tR 50.4 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel 
Chemical Ind., Ltd.) hexane/i-PrOH, 99.5:0.5, 1.0 mL/min] to be 90% ee. [α]D26 = -398.8° (c 
0.64, CHCl3). 1H NMR (400 MHz, CDCl3): δ 1.62-1.76 (m, 2H), 2.30 (s, 3H), 2.37 (t, J = 
6.8 Hz, 2H), 2.53-2.63 (m, 2H), 2.91 (d, J = 15.2 Hz, 1H), 2.98 (d, J = 15.2 Hz, 1H), 7.06 (d, 
J = 8.4 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H). 
13C NMR (151 MHz, CDCl3): δ 21.0, 21.2, 35.8, 40.8, 50.3, 53.6, 124.2 (q, J = 272.1 Hz, 
1C), 125.5 (q, J = 3.8 Hz, 1C), 126.9, 127.4, 128.6 (q, J = 32.3 Hz, 1C), 129.5, 136.4, 143.4, 
151.8, 210.2. 19F NMR (376 MHz, CDCl3): δ -62.5 (s, 3F). HRMS (ESI): Calcd. for 
C20H20F3O
+ ([M+H]+): 333.1461 Found: 333.1462. 
 
 (S)-3-(3-methoxyphenyl)-3-(p-tolyl)cyclohexan-1-one (2t): Prepared 
according to General Procedure C from 3-(3-methoxyphenyl)-cyclohex-2-en-
1-one 1g (60.7 mg, 0.300 mmol) and 4-methylphenylboronic acid (122 mg, 
0.900 mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 
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to 90:10 hexane: EtOAc) to give 2t (63.6 mg, 0.216 mmol, 72%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 91.7 min (major); 
tR 106.1 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 98:2, 1.0 mL/min] to be 93% ee. [α]D22 = -143.8° (c 0.67, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ 1.66-1.72 (m, 2H), 2.30 (s, 3H), 2.34 (t, J = 6.8 Hz, 2H), 2.53 (d, J = 
6.0 Hz, 1H), 2.55 (d, J = 6.0 Hz, 1H), 2.91 (d, J = 15.6 Hz, 1H), 2.95 (d, J = 15.6 Hz, 1H), 
3.75 (s, 3H), 6.72 (ddd, J = 8.4, 2.4, 0.8 Hz, 1H), 6.77-6.80 (m, 2H), 7.07-7.11 (m, 4H), 7.19 
(t, J = 8.4 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 21.0, 21.2, 35.9, 40.9, 50.2, 53.9, 55.2, 
111.0, 113.6, 119.5, 126.9, 129.3, 129.5, 135.9, 144.2, 149.3, 159.7, 210.9. HRMS (ESI): 
Calcd. for C20H23O2
+ ([M+H]+): 295.1693 Found: 295.1691.    
 
 (S)-3-(2-methoxyphenyl)-3-(p-tolyl)cyclohexan-1-one (2u): Prepared 
according to General Procedure C from 3-(2-methoxyphenyl)-cyclohex-2-en-
1-one 1h (60.7 mg, 0.300 mmol) and 4-methylphenylboronic acid (122 mg, 
0.900 mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 
to 95:5 hexane: EtOAc) to give 2u (24.7 mg, 0.084 mmol, 28%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 16.2 min (minor); 
tR 17.7 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 80:20, 1.0 mL/min] to be 80% ee. [α]D19 = -175.6° (c 0.68, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ 1.59-1.68 (m, 2H), 2.28 (s, 3H), 2.33 (t, J = 6.8 Hz, 2H), 2.36-2.42 (m, 
1H), 2.78-2.84 (m, 1H), 2.82, (d, J = 16.0 Hz, 1H), 3.15 (d, J = 16.0 Hz, 1H), 3.37 (s, 3H), 
6.78 (d, J = 7.6 Hz, 1H), 6.96 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 9.2 Hz, 2H), 7.04 (d, J = 9.2 
Hz, 2H), 7.22 (t, J = 7.6 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 
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21.0, 21.1, 34.5, 41.0, 49.3, 52.9, 55.4, 113.2, 120.6, 126.4, 127.7, 128.2, 128.6, 135.0, 135.8, 
144.9, 157.7, 212.0. HRMS (ESI): Calcd. for C20H23O2
+ ([M+H]+): 295.1693 Found: 
295.1694.   
 
 (R)-3-phenyl-3-(m-tolyl)cyclohexan-1-one (2v): Prepared according to 
General Procedure C from 3-phenylcyclohex-2-en-1-one 1b (51.6 mg, 0.300 
mmol) and 3-methylphenylboronic acid (122 mg, 0.900 mmol). The crude 
product was purified with a CombiFlash system (4 g column, 100:0 to 90:10 hexane: EtOAc) 
to give 2v (60.3 mg, 0.228 mmol, 76%) as a colorless oil. The enantiomeric excess was 
determined by HPLC analysis (220 nm, 25 °C) tR 28.4 min (minor); tR 32.4 min (major) 
[Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 95:05, 
1.0 mL/min] to be 88% ee. [α]D22 = +122.4° (c 0.92, CHCl3). 1H NMR (400 MHz, CDCl3): δ 
1.65-1.72 (m, 2H), 2.30 (s, 3H), 2.34-2.37 (t, J = 6.8 Hz, 2H), 2.57 (d, J = 6.0 Hz, 1H), 2.59 
(d, J = 6.0 Hz, 1H), 2.96 (s, 2H), 7.00-7.02 (m, 3H), 7.15-7.23 (m, 4H), 7.26-7.30 (m, 2H). 
13C NMR (101 MHz, CDCl3): δ 21.2, 21.8, 35.8, 40.9, 50.3, 53.8, 124.2, 126.3, 127.0, 127.1, 
127.7, 128.4, 128.5, 138.1, 147.3, 147.5, 211.0. HRMS (ESI): Calcd. for C19H20O
+ 
([M+H]+): 265.1587 Found: 265.1590.   
 
 (S)-3-phenyl-3-(p-tolyl)cyclohexan-1-one (ent-2q): Prepared according to 
General Procedure C from 3-(4-methylphenyl)-cyclohex-2-en-1-one 1d (55.8 
mg, 0.300 mmol) and phenylboronic acid (110 mg, 0.900 mmol). The crude 
product was purified by flash chromatography (90:10 hexane: EtOAc) to give (ent)-2q (55.5 
mg, 0.210 mmol, 70%) as a colorless oil. The enantiomeric excess was determined by HPLC 
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analysis (220 nm, 25 °C) tR 44.6 min (major); tR 59.4 min (minor) [Chiracel AS-H (0.46 cm x 
25 cm) (from Daicel Chemical Ind., Ltd.) hexane/i-PrOH, 99:01, 1.0 mL/min] to be 88% ee. 
[α]D22 = +11.6° (c 0.86, CHCl3). 1H and 13C NMR data matched NMR data for (R)-2q. 
HRMS (ESI): Calcd. for C19H21O
+ ([M+H]+): 265.1587 Found: 265.1584.  
 
 (R)-3-(4-methoxyphenyl)-3-phenylcyclohexan-1-one (ent-2a): Prepared 
according to General Procedure C from 3-phenylcyclohex-2-en-1-one 1b 
(51.6 mg, 0.300 mmol) and 4-methoxyphenylboronic acid (137 mg, 0.900 
mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 to 
90:10 hexane: EtOAc) to give (ent)-2b (37.0 mg, 0.132 mmol, 44%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (220 nm, 25 °C) tR 21.7 min (major); 
tR 36.4 min (minor) [Chiracel OJ-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
hexane/i-PrOH, 75:25, 1.0 mL/min] to be 80% ee. [α]D22 = -8.3° (c 0.24, CHCl3). 1H and 13C 
NMR data matched NMR data for (S)-2b. HRMS (ESI): Calcd. for C19H21O2
+ ([M+H]+): 
281.1536 Found: 281.1526.      
 
 (S)-3-(4-methoxyphenyl)-3-(p-tolyl)cyclopentan-1-one (2w): Prepared 
according to General Procedure C from 3-(4-methoxyphenyl)-cyclopent-2-en-
1-one 1e (56.4 mg, 0.300 mmol) and 4-methylphenylboronic acid (122 mg, 
0.900 mmol). The crude product was purified with a CombiFlash system (4 g column, 100:0 
to 90:10 hexane: EtOAc) to give 2w (50.5 mg, 0.180 mmol, 60%) as a colorless oil. The 
enantiomeric excess was determined by HPLC analysis (254 nm, 25 °C) tR 22.9 min (minor); 
tR 25.5 min (major) [Chiracel AS-H (0.46 cm x 25 cm) (from Daicel Chemical Ind., Ltd.) 
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hexane/i-PrOH, 80:20, 1.0 mL/min] to be 87% ee. [α]D21 = -53.9° (c 1.06, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ 2.28 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 2.66 (d, J = 7.6 Hz, 1H), 2.68 (d, 
J = 7.6 Hz, 1H), 2.93 (d, J = 17.6 Hz, 1H), 2.98 (d, J = 17.6 Hz, 1H), 3.77 (s, 3H), 6.83 (ddd, 
J = 9.2, 2.8, 2.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.83 (ddd, J = 
9.2, 2.8, 2.4 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 21.0, 35.6, 36.7, 51.0, 52.2, 55.3, 
113.9, 126.6, 127.8, 129.3, 136.0, 139.0, 144.1, 158.0, 217.8. HRMS (ESI): Calcd. for 
C19H21O2
+ ([M+H]+): 281.1536 Found: 281.1542. 
 
Synthesis of (S,E)-1-(2,4-dinitrophenyl)-2-(3-(4-methoxyphenyl)-3-(p-
tolyl)cyclohexylidene)hydrazine ((S,E)-4a) 
O
O
N
O
HN
NO2
NO2
H
N
H2N
NO2
NO2
acetic acid (cat.)
toluene, relux, 16 h2a (S,E)-4a
(1 equiv)
 
To an oven dried round bottom flask was added (S)-3-(4-methoxyphenyl)-3-(p-
tolyl)cyclohexan-1-one 2a (0.181 g, 0.614 mmol, 89% ee), 2,4-dinitrophenylhydrazine 
(0.122 g, 0.614 mmol) and 20 mL of anhydrous toluene. A drop of acetic acid was added to 
the reaction mixture and the resulting solution was refluxed with a Dean-Stark trap for 16 h. 
The reaction mixture was then concentrated under vacuum. The crude reaction mixture was 
purified with flash silica gel chromatography using dichloromethane:hexane (6:4) as an 
eluent to give a mixture of (S,E)-1-(2,4-dinitrophenyl)-2-(3-(4-methoxyphenyl)-3-(p-
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tolyl)cyclohexylidene)hydrazine (S,E)-4a and (S,Z)-1-(2,4-dinitrophenyl)-2-(3-(4-
methoxyphenyl)-3-(p-tolyl)cyclohexylidene)hydrazine (S,Z)-4a in 80 % yield with 3.3:1.0 dr. 
The resulting mixture was recrystallized from methanol to obtain yellow single crystals of 
(S,E)-4a for single crystal XRD analysis. [α]D24 = +334.0° (c 1.0, CHCl3). 1H NMR of (S,E)-
4a (400 MHz, CDCl3): δ 1.67-1.73 (m, 2H), 2.29 (s, 3H), 2.46-2.54 (m, 4H), 3.10 (d, J = 
15.2 Hz, 1H), 3.14 (d, J = 15.2 Hz, 1H), 3.76 (s, 3H), 6.81 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 
8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 9.6 Hz, 1H), 8.35 
(dd, J = 9.6, 2.4 Hz, 1H), 9.13 (d, J = 2.4 Hz, 1H), 11.21 (s, 1H). 13C NMR of (S,E)-4a (101 
MHz, CDCl3):  20.9, 21.0, 26.3, 36.1, 47.0, 47.6, 55.3, 113.8, 116.4, 123.8, 127.1, 128.3, 
129.3, 130.2, 131.2, 135.8, 137.7, 139.5, 144.7, 145.4, 157.8, 159.66, 159.68. HRMS (ESI): 
Calcd. for C26H27N4O5
+ ([M+H]+): 475.1976 Found: 475.1968. 
 
Absolute stereochemistry and structure of (S,E)-4a: 
Single crystal X-ray structure determination of 4а was performed using Cu radiation to 
determine the absolute configuration of the molecule. The systematic absences in the 
diffraction data were consistent with the P1 space group. The position of almost all non-
hydrogen atoms were found by direct methods. The remaining atoms were located in an 
alternating series of least-squares cycles on difference Fourier maps. All non-hydrogen atoms 
were refined in full-matrix anisotropic approximation. All hydrogen atoms were placed in the 
structure factor calculation at idealized positions and were allowed to ride on the neighboring 
atoms with relative isotropic displacement coefficients. Flack, Hooft, and Parsons parameters 
calculated with PLATON software (as 0.06(8), 0.08(8), and 0.07(7) respectively) are 
consistent with our assignment of the absolute configuration. CCDC 1544809 contains the 
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supplementary crystallographic data for this paper. These data can be obtained free of charge 
from the Cambridge Crystallographic Data Centre 
via http://www.ccdc.cam.ac.uk/data_request/cif. 
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CHAPTER 3 
CONCLUSION 
 
 
 In conclusion, this thesis describes the development of enantioselective, 
palladium(II)-catalyzed conjugate additions of arylboronic acids to form compounds 
containing bis-benzylic quaternary stereocenters. Prior to this work, enantioselective, 
palladium-catalyzed conjugate additions of arylboronic acids to β-aryl β,β-disubstituted 
cyclic enones were unsuccessful. The thesis describes the studies involved in the 
development of enantioselective, palladium-catalyzed conjugate additions of arylboronic 
acids to β-aryl β,β-disubstituted cyclic enones. This includes identification of reaction 
conditions by studying impact of chiral ligands, solvents, reaction atmosphere and 
temperature on palladium-catalyzed conjugate additions of arylboronic acids to β-aryl β,β-
disubstituted enones. We also studied impact of water, reaction atmosphere and temperature 
on protodeboronation of arylboronic acids which is a major undesired pathway in palladium-
catalyzed conjugate additions of arylboronic acids. We adopted iterative addition strategy to 
maintain low concentration of arylboronic acids and hence a low rate of protodeboronation. 
This strategy allows us to access different ketone products containing bis-benzylic quaternary 
stereocenters by additions of a wide array of arylboronic acids to a variety of β-aryl β,β-
disubstituted enones in up to 92% yield and 93% enantioselectivity.  
However, the method developed has some limitations. Additions of ortho-substituted 
arylboronic acids and heteroarylboronic acids, which are more susceptible to 
protodeboronation, were usually low yielding and unsuccessful in some cases. This method, 
however, allows access to ketone products containing ortho-substitution on aryl groups by 
additions of arylboronic acids to ortho-substituted β-aryl β,β-disubstituted enones. Additions 
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of arylboronic acid to β-aryl β,β-disubstituted cyclohepten-2-one and acyclic enone were low 
yielding. Further work should be done to overcome these limitations. A catalyst system 
which allows faster conjugate addition reactions and suppresses protodeboronation pathways 
is desirable to allow additions of challenging substrates such as ortho-substituted arylboronic 
acids and heteroarylboronic acids. Future plan involves studies towards development of 
enantioselective additions of arylboronic acids to heterocyclic electrophiles containing aryl 
substitution at 2-position.  
 
Scheme 1. Future directions  
 
 
Future plan includes synthesis of estrogen receptor β antagonist RO01. After 
enantioselective, palladium-catalyzed conjugate additions of ortho-substituted arylboronic 
acids to β-aryl β,β-disubstituted cyclohepten-2-one are developed, the reaction can be used as 
a key step to access ketone product II. Current development in photoredox catalysis 
involving nickel-mediated alcohol coupling allows bond formation between arylbromides 
and aliphatic alcohols.1 However, oxidative coupling between aryl alcohols and enolates is 
unprecedented. We propose to develop a diastereoselective, photoredox, nickel-mediated 
oxidative coupling between aryl alcohols and enolates to give dihydrobenzofuarn fused 
ketone III. A sequence of Wolff Kishner reduction of III, followed by demethylation of IV 
can yield RO01. 
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 Scheme 2: Proposed synthetic route for synthesis of RO01 
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